Proteasome inhibitors: A novel tool to suppress human cytomegalovirus replication and virus-induced immune modulation

Antiviral Therapy

Volumn 8, Issue 6, 2003, Pages 555-567

  Prösch, Susanna ^a   Priemer, Christina ^a   Höflich, Conny ^a   Liebenthal, Christa ^a   Babel, Nina ^a   Krüger, Detlev H ^a   Volk, Hans Dieter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLISOLEUCYLGLUTAMYL O TERT BUTYL ALANYLLEUCINAL; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINE; BENZYLOXYCARBONYLLEUCYLLEUCYLPHENYLALANINAL; GANCICLOVIR; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MG 262; PROTEASOME INHIBITOR; PROTEIN; PROTEIN IE1; PROTEIN P52; PROTEIN P68; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA REPLICATION; DRUG EFFECT; EMBRYO; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IN VITRO STUDY; LUNG FIBROBLAST; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN SYNTHESIS; UPREGULATION; VIRUS ASSEMBLY; VIRUS GENE; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS STRAIN;

CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; CYTOMEGALOVIRUS; HL-60 CELLS; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-8; LEUPEPTINS; MULTIENZYME COMPLEXES; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; RANTES; TRANS-ACTIVATORS; TUMOR NECROSIS FACTOR-ALPHA; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 0348223942     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Coux O, Tanaka K & Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annual Review of Biochemistry 1996; 65:2165-2171.
2. Rivett AJ & Gardner RC. Proteasome inhibitors: from in vitro uses to clinical trials. Journal of Peptide Science 2000; 6:478-488.
3. Goldberg AL & Rock K. Not just research tools - proteasome inhibitors offer therapeutic promise. Nature Medicine 2002; 8:338-340.
4. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, Wolf RE, Huang J, Brand S, Elliott PJ, Lazarus D, McCormack T, Parent L, Stein R, Adams J & Grisham MB. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proceedings of the National Academy of Sciences, USA 1998; 95:15671-15676.
5. Elliott PJ, Pien CS, McCormack TA, Chapman ID & Adams J. Proteasome inhibition: a novel mechanism to combat asthma. Journal of Allergy & Clinical Immunology 1999; 104:294-300.
6. Vanderlugt CL, Rahbe SM, Elliott PJ, dalCanto MC & Miller SD. Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. Journal of Autoimmunity 2000; 14:205-211.
7. Zhang L, Zhang ZG, Zhang RL, Lu M, Adams J, Elliott PJ & Chopp M. Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 2001; 32:2926-2931.
8. Meiners S, Laule M, Rother W, Guenther C, Prauka I, Muschick P, Baumann G, Kloetzel PM & Stangl K. Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation 2002; 105:483-489.
9. Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R & Boehncke WH. Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. Journal of Clinical Investigation 2002; 109:671-679.
10. Palombella V, Rando O, Goldberg A & Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-κB precursor protein and the activation of NF-κB. Cell 1994; 78:773-785.
11. Silverman N & Maniatis T. NF-κB signaling pathways in mammalian and insect innate immunity. Genes & Development 2001; 15:2321-2342.
12. Li Q & Verma IM. NF-κB regulation in the immune system. Nature Reviews Immunology 2002; 2:725-734.
13. Döcke WD, Prösch S, Fietze E, Kimel V, Zuckermann H, Kluge C, Syrbe U, Krüger DH, von Baehr R & Volk HD. Cytomegalovirus reactivation and tumor necrosis factor. Lancet 1994; 343:268-269.
14. Fietze E, Prösch S, Reinke P, Stein J, Döcke WD, Staffa G, Loening S, Devaux S, Emmrich F, von Baehr R, Krüger DH & Volk HD. Cytomegalovirus infection in transplant recipients: role of tumour necrosis factor. Transplantation 1994; 58:675-680.
15. Kutza AST, Muhl E, Hackstein H, Kirchner H & Bein G. High incidence of active cytomegalovirus infection among septic patients. Clinical Infectious Diseases 1998; 26:1076-1082.
16. Asadullah K, Prösch S, Audring H, Büttnerova L, Volk HD, Sterry W & Döcke WD. A high prevalence of cytomegalovirus antigenemia in patients with moderate to severe chronic plaque psoriasis: an association with systemic tumor necrosis factor over expression. British Journal of Dermatology 1999; 141:94-102.
17. Heininger A, Vogel U, Aepinus C & Hamprecht K. Fatal human cytomegalovirus disease after severe multiple trauma. Critical Care Medicine 2000; 28:563-566.
18. Heininger A, Jahn G, Engel MA, Notheisen T, Unertl K & Hamprecht K. Human cytomegalovirus infections in nonimmunosuppressed critical ill patients. Critical Care Medicine 2001; 29:541-547.
19. Hahn G, Jones R & Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proceedings of the National Academy of Sciences, USA 1998; 95:3937-3942.
20. Söderberg-Naucler C, Fish KN, Smith P, Allan-Yorke J & Nelson JA. Reactivation of latent human cytomegalovirus by allogenic stimulation of blood cells from healthy donors. Cell 1997; 3:119-126.
21. Söderberg-Naucler C, Fish KN & Nelson JA. Interferon-g and tumor necrosis factor-a specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of this cytokines. Journal of Clinical Investigation 1997; 100:1-10.
22. Hummel M, Zhang Z, Yan S, Deplaen I, Golia P, Varghese T, Thomas G & Abecassis MI. Allogenic transplantation induces expression of cytomegalovirus immediate-early genes in vivo: a model for reactivation from latency. Journal of Virology 2001; 75:4814-4822.
23. Stein J, Volk HD, Liebenthal C, Krüger DH & Prösch S. Tumor necrosis factor alpha stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells. Journal of General Virology 1993; 74:2333-2338.
24. Prösch S, Volk HD, Reinke P, Pioch K, Döcke WD & Krüger DH. Human cytomegalovirus infection in transplant recipients: role of TNFα for reactivation and replication of human cytomegalovirus. In: Monographs in Virology. Edited by Scholz M, Rabenau HF, Doerr HW & Cinatl J Jr (CMV-related immunopathology). 1998; vol 21:pp29-42. Karger, Basel, Switzerland.
25. Prösch S, Staak K, Stein J, Liebenthal C, Stamminger T, Volk HD & Krüger DH. Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNFα is mediated via induction of NF-κB. Virology 1995; 208:197-206.
26. Prösch S, Wuttke R, Krüger DH & Volk HD. NF-κB - a potential therapeutic target for inhibition of human cytomegalovirus (re)activation? Biological Chemistry 2002; 383:1601-1609.
27. Sambucetti LC, Cherrington JM, Wilkinson GWG & Mocarski ES. NF-κB activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO Journal 1989; 8:4251-4258.
28. Michelson S. Mechanisms of immunosuppression by human cytomegalovirus. In: Monographs in Virology. Edited by Scholz M, Rabenau HF, Doerr HW & Cinatl J Jr (CMV-related immunopathology). 1998; vol 21:pp12-28. Karger, Basel, Switzerland.
29. Scholz M, Vogel JU, Blaheta RA, Doerr HW & Cinatl J Jr. Cytomegalovirus, oxidative stress and inflammation as independent pathomechanisms: need for novel therapeutic strategies. In: Monographs in Virology. Edited by Scholz M, Rabenau HF, Doerr HW & Cinatl J Jr (CMV-related immunopathology). 1998; vol 21:pp 90-105. Karger, Basel, Switzerland.
30. Scholz M, Doerr HW & Cinatl J. Inhibition of cytomegalovirus immediate early gene expression: a therapeutical option? Antiviral Research 2001; 49:129-145.
31. Nordoy I, Müller F, Nordal KP, Rollag H, Aukrust P & Frpland SS. Chemokines and soluble adhesion molecules in renal transplant recipients with cytomegalovirus infection. Clinical & Experimental Immunology 2000; 120:333-337.
32. Murayama T, Ohara Y, Obuchi M, Khabar KSA, Higashi H, Mukaida N & Matsushima K. Human cytomegalovirus induces interleukin-8 production by a human monocytic cell line, THP-1, through acting concurrently on AP-1 and NF-κB-Binding sites of the interleukin-8 gene. Journal of Virology 1997; 71:5692-5695.
33. Carlquist JF, Edelman L, Bennion DW & Anderson JL. Cytomegalovirus induction of interleukin 6 in lung fibroblasts occurs independently of active infection and involves a G protein and the transcription factor NF-κB. Journal of Infectious Diseases 1999; 179:1094-1100.
34. Kronschnabl M & Stamminger T. Synergistic induction of intercellular adhesion molecule-1 by the human cytomegalovirus transactivators IE2 p86 and pp71 is mediated via an SP-1 binding site. Journal of General Virology 2003; 84:61-73.
35. Grillone LR & Lanz R. Fomivirsen. Drugs Today (Barc.) 37:245-255.
36. Lee DH & Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. Trends in Cell Biology 1998; 8:397-403.
37. Fickenscher H, Stamminger T, Rüger R & Fleckenstein B. The role of a repetitive palindromic sequence element in the human cytomegalovirus major immediate early enhancer. Journal of General Virology 1989; 70:107-123.
38. Beutler T, Höflich C, Steven PA, Krüger DH & Prösch S. Downregulation of the epidermal growth factor receptor by human cytomegalovirus infection in human fetal lung fibroblasts. American Journal of Respiratory Cell & Molecular Biology 2003; 28:86-94.
39. Stamminger T, Fickenscher H & Fleckenstein B. The cell type-specific induction of the major immediate early enhancer of human cytomegalovirus by cyclic AMP. Journal of General Virology 1990; 71:105-113.
40. Craigen JL & Grundy JE. Cytomegalovirus induced upregulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. Transplantation 1996; 62:1102-1108.
41. Poon APW, Silverstein SJ & Roizman B. An early regulatory function required in a cell type-dependent manner is expressed by the genomic but not the cDNA copy of the herpes simplex virus 1 gene encoding infected cell protein 0. Journal of Virology 2002; 76:9744-9755.
42. Marchinin A, Liu H & Zhu H. Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes. Journal of Virology 2001; 75:1870-1878.
43. Ghosh S & Karin M. Missing pieces in the NF-κB puzzle. Cell 2002; 109:S81-S96.
44. Yurochko AD & Huang ES. Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression. Journal of Immunology 1999; 162:4806-4816.
45. cipl in cells productively infected with human cytomegalovirus. Journal of Virology 2001; 75:3613-3625.
46. Lebbe C, Blum L, Pellet C, Blanchard G, Verola O, Morel P, Danne O & Calvo F. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS (Hagerstown) 1998; 12:F45-F49.
47. Panjonk F, Himmelsbach J, Riess K, Sommer A & McBride WH. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization on non-HIV-associated human cancer cells. Cancer Research 2002; 62:5230-5235.
48. Piccinini M, Rinaudo MT, Chiapello N, Ricotti E, Baldovino S, Mostert M & Tovo PA. The human 26S proteasome is a target of antiviral agents. AIDS 2002; 16:693-700.
49. Schubert U, Ott DE, Chertova EN, Welker R, Tessmer U, Princiotta MF, Bennink JR, Kräusslich HG & Yewdell JW. Proteasome inhibition interferes with gag polyprotein processing, release and maturation of HIV-1 and HIV-2. Proceedings of the National Academy of Sciences, USA 2000; 97:13057-13062.
50. Jacque JM, Fernandez B, Arenzana-Seisdedos F, Thomas D, Baleux F, Virelizier JL & Bachelerie F. Permanent occupancy of the immunedeficiency virus type 1 enhancer by NF-κB is needed for persistent viral replication in monocytes. Journal of Virology 1996; 70:2930-2938.
51. Scholz M, Hamann A, Blaheta RA, Auth MKH, Encke A & Markus BH. Cytomegalovirus- and interferon-related effects on human endothelial cells: cytomegalovirus infection reduces upregulation of HLA class II antigen expression after treatment with interferon-gamma. Human Immunology 1992; 35:230-239.
52. Grundy JE & Downes KL. Up-regulation of LFA-3 and ICAM-1 on the surface of fibroblasts infected with cytomegalovirus. Immunology 1993; 78:405-412.
53. Michelson S, Dal Monte P, Zipeto D, Bodaghi B, Laurent L, Arenzana-Seisdedos F, Virelizier JL & Landini MP. Modulation of RANTES production by human cytomegalovirus in fibroblasts. Journal of Virology 1997; 71:6495-6500.
54. Browne EP, Wing B, Coleman D & Shenk T. Altered cellular mRNA levels in human cytomegalovirus-infected fibroblasts: viral block to the accumulation of antiviral mRNAs. Journal of Virology 2001; 75:12319-12330.
55. Hidi R, Riches V, Al-Ali M, Cruikshank WW, Center DM, Holgate ST & Djukanovic R. Role of B/-CD28/CTLA-4 costimulation and NF-&B in allergen-induced T-cell chemotaxis by IL-16 and RANTES. Journal of Immunology 2000; 164:412-418.
56. Wu HM, Wen HC & Lin WW. Proteasome inhibitors stimulate Interleukin-8 via Ras and apoptosis signal-regulating kinase-dependent extracellular signal-related kinase and c-jun N-terminal kinase activation. American Journal of Respiratory Cell & Molecular Biology 2002; 27:234-243.
57. +-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. Journal of Virology 1999; 73:8179-8184.